48
Participants
Start Date
November 16, 2022
Primary Completion Date
June 20, 2028
Study Completion Date
June 20, 2028
Zilovertamab vedotin
Administered via intravenous (IV) infusion on day 1 and day 8 of Q3W cycles
Pembrolizumab
Administered via IV infusion on Day 1 of each 6 week cycle.
MK-3120
Administered as an IV infusion on Day 1, Day 15, and Day 29 of each 6 week cycle.
Rigshospitalet-Dept. of Oncology ( Site 1701), Copenhagen
Royal Brisbane and Women's Hospital-Medical Oncology Clinical Trials Unit, Cancer Care Services ( Site 1952), Brisbane
UPMC Hillman Cancer Center ( Site 1014), Pittsburgh
Hospital Clinico San Carlos ( Site 1765), Madrid
Cleveland Clinic-Taussig Cancer Center ( Site 1036), Cleveland
Indiana University Melvin and Bren Simon Cancer Center ( Site 1011), Indianapolis
Siteman Cancer Center ( Site 1038), St Louis
Anschutz Cancer Pavilion ( Site 1017), Aurora
University of California, Irvine (UCI) Health - UC Irvine Medical Center ( Site 1045), Orange
Rambam Health Care Campus-Oncology ( Site 1501), Haifa
Rabin Medical Center-Oncology ( Site 1504), Petah Tikva
Sheba Medical Center-ONCOLOGY ( Site 1503), Ramat Gan
FALP-UIDO ( Site 1151), Santiago
Bradford Hill ( Site 1155), Santiago
Severance Hospital, Yonsei University Health System ( Site 1903), Seoul
Asan Medical Center ( Site 1901), Seoul
Samsung Medical Center ( Site 1902), Seoul
Hospital Universitari Vall d'Hebron ( Site 1767), Barcelona
Merck Sharp & Dohme LLC
INDUSTRY